UnitedHealth Group Incorporated is expected to report Q2 2026 revenue of $118.50 billion and earnings per share of $4.84, with the stock currently trading at $612.45 against a consensus analyst price target of $685.00. The primary focus for investors this quarter is the Medical Care Ratio (MCR), which provides critical insight into medical cost trends relative to premium revenue.
Management's commentary on healthcare utilization within the Medicare Advantage segment remains a top concern following recent volatility in outpatient procedure volumes. Additionally, analysts are looking for continued recovery signals within the Optum division and updates on the long-term margin impacts of regulatory reimbursement changes.